PMID
Cmpds
Data
Article Title
Organization
37
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.

Shandong University
52
Discovery of 4-((3'R,4'S,5'R)-6 -Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2 -oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3 -indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Deve

University of Michigan Comprehensive Cancer Center
13
Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists.

Peking Union Medical College
16
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locke

Bristol Myers Squibb
30
Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.

Beijing Pearl Biotech
2
Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL).

University of Michigan
8
Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importina-2 Expression, and Induce Antitumor Effects against Human Glioma.

University of Hawaii At Hilo
26
Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.

Beijing Pearl Biotech
29
Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors.

Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
1
Discovery of a Cyclic Boronic Acid -Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.

Rempex Pharmaceuticals
26
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.

Amgen
33
Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.

Amgen
11
Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.

University of Hawaii At Hilo
15
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.

Bristol Myers Squibb
47
Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.

Amgen
23
Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.

Amgen
46
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.

Amgen
2
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).

The University of Texas M.D. Anderson Cancer Center
4
Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level.

The University of Texas M.D. Anderson Cancer Center
14
Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents.

University of California San Francisco
1
Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists of -catenin/TCF transcription.

University of Michigan
48
Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.

State Key Laboratory of Bioreactor Engineering
10
A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.

University of Michigan
1
Development of oleanane-type triterpenes as a new class of HCV entry inhibitors.

Peking University
33
Rational design and binding mode duality of MDM2-p53 inhibitors.

Amgen
11
Novel inhibitors of bacterial virulence: development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression.

University of Michigan
10
Structure-based design of novel inhibitors of the MDM2-p53 interaction.

Amgen
5
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

University of Michigan
37
Discovery and optimization of benzenesulfonanilide derivatives as a novel class of 11ß-HSD1 inhibitors.

Amgen
23
Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11 beta-HSD1 inhibitors.

Amgen
11
Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.

Amgen
10
Quadruplex-interactive agents as telomerase inhibitors: synthesis of porphyrins and structure-activity relationship for the inhibition of telomerase.

University of Texas At Austin
26
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.

University of Hawaii At Hilo
46
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.

St. Jude Children'S Research Hospital
16
Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.

University of Michigan
18
Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11ß-HSD1 inhibitors.

Amgen
39
The synthesis and SAR of novel diarylsulfone 11ß-HSD1 inhibitors.

Amgen
9
Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity.

Pfizer
31
Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).

TBA
2
Histone deacetylase inhibitors through click chemistry.

The Ohio State University
2
Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.

Amgen
48
Design of Potent Small-Molecule Stimulator of Interferon Gene Inhibitor and Stimulator of Interferon Gene Mutant-Specific Degrader.

University of Michigan
53
Design of an Oral STING Agonist through Intramolecular Hydrogen Bond Ring Mimicking to Achieve Complete Tumor Regression.

University of Michigan
16
Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors.

Insilico Medicine Shanghai Ltd
6
Discovery of SMD-3236: A Potent, Highly Selective and Efficacious SMARCA2 Degrader for the Treatment of SMARC4-Deficient Human Cancers.

University of Michigan
3
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.

University of Michigan
40
Structure-Based Development of Novel Spiro-Piperidine ASH1L Inhibitors.

University of Michigan
8
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα).

University of Michigan
8
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer.

University of Michigan
28
Discovery of Chalcone Derivatives as Bifunctional Molecules with Anti-SARS-CoV-2 and Anti-inflammatory Activities.

East China Normal University
7
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.

University of Michigan
26
Discovery of 3-hydroxymethyl-azetidine derivatives as potent polymerase theta inhibitors.

Insilico Medicine Shanghai Ltd
14
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.

University of Michigan
33
Benzodioxane Carboxamide Derivatives As Novel Monoamine Oxidase B Inhibitors with Antineuroinflammatory Activity.

Zunyi Medical University
14
Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors.

Insilico Medicine Shanghai Ltd
2
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.

University of Michigan
18
Discovery and Optimization of Selective Brain-Penetrant EBP Inhibitors that Enhance Oligodendrocyte Formation.

Genentech
2
Discovery of a Potent Nicotinamide Phosphoribosyltransferase Activator for Improving Aging-associated Dysfunctions.

Second Military Medical University (Naval Medical University)
18
The mechanism of UNC-51-like kinase 1 and the applications of small molecule modulators in cancer treatment.

Shenyang Pharmaceutical University
29
Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity

University of Michigan
24
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.

University of Michigan
30
Systematic Study of Heteroarene Stacking Using a Congeneric Set of Molecular Glues for Procaspase-6.

University Of California
1
Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect.

Peking University
23
Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.

University of Michigan
7
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

University of Michigan
3
Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong

University of Michigan
4
Discovery of

University of Michigan
4
Fluorescent and theranostic probes for imaging nicotinamide phosphoribosyl transferase (NAMPT).

Second Military Medical University (Naval Medical University)
40
Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer.

University of Michigan
1
PROTACs: New method to degrade transcription regulating proteins.

Shenyang Pharmaceutical University
20
Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors.

Sichuan University
6
Dual-target kinase drug design: Current strategies and future directions in cancer therapy.

Sichuan University
10
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation.

Second Military Medical University (Naval Medical University)
1
Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD).

Wuxi Apptec
11
Targeting SHP2 as a therapeutic strategy for inflammatory diseases.

Shenyang Pharmaceutical University
18
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.

Bristol Myers Squibb
29
Discovery of (

Bristol Myers Squibb
26
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1

Bristol Myers Squibb
24
Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models.

AstraZeneca
17
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.

Bristol Myers Squibb
27
Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.

University of Chinese Academy of Sciences
35
Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression.

University of Tennessee Health Science Center
1
Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.

Southwest Jiaotong University
39
Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy.

University of Michigan
38
Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.

Oric Pharmaceuticals
2
SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.

University of Michigan
22
Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.

Bristol Myers Squibb
2
Withanolides from dietary tomatillo suppress HT1080 cancer cell growth by targeting mutant IDH1.

Shenyang Pharmaceutical University
3
Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.

Shenyang Pharmaceutical University
42
Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression.

University of Michigan
26
Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD).

Luoxin Pharmaceutical (Shanghai) Co.
9
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.

Bristol Myers Squibb
13
Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidines as atypical protein kinase C inhibitors to control retinal vascular permeability and cytokine-induced edema.

University of Michigan
5
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.

Qpex Biopharma
35
EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.

University of Michigan
37
Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.

East China University of Science & Technology
11
Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.

East China University of Science and Technology
23
Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.

Merck
21
Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).

Oric Pharmaceuticals
44
Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors.

Sichuan University
7
Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFR

East China University of Science and Technology
26
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.

TBA
11
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.

TBA
30
Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere.

TBA
27
Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.

Yanbian University
1
Inhibition of human telomerase by a G-quadruplex-interactive compound.

Institute For Drug Development
19
Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4.

Amgen
21
Synthesis and antibacterial evaluation of anziaic acid and analogues as topoisomerase I inhibitors.

University of Hawai'I At Hilo
10
Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC).

University of Pennsylvania
29
Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.

TBA
51
Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.

University of Michigan
4
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.

University of Michigan Comprehensive Cancer Center
32
Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.

Indiana University School of Medicine
29
Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.

University of Michigan
10
Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.

University of Hawai'I At Hilo
37
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.

University of Michigan
28
Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).

Oric Pharmaceuticals
31
Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.

TBA
21
Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation.

Shanghai Institute of Materia Medica (Simm)
2
Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer.

Shenyang Pharmaceutical University
18
Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.

East China University of Science and Technology
27
Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability.

University of Michigan
11
Synthesis, evaluation, and CoMFA study of fluoroquinophenoxazine derivatives as bacterial topoisomerase IA inhibitors.

University of Hawaii At Hilo
21
Potent and selective azaindole inhibitors of CDK8 and CDK19

Dana-Farber Cancer Institute
39
Substituted carbazole compounds

Bristol Myers Squibb
269
ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF

Hangzhou Healzen Therapeutics Co.
24
3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

Boehringer Ingelheim International
2
Tricyclic compounds as Cyp1 inhibitors

The General Hospital
92
Cyano-substituted heterocycles with activity as inhibitors of USP30

Mission Therapeutics
49
1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER

Genentech
73
19-NOR neuroactive steroids and methods of use thereof

Sage Therapeutics
43
Pyrimidine compounds as JAK kinase inhibitors

Theravance Biopharma R&D Ip
1
Kinetic characterization of a slow-binding inhibitor of Bla2: thiomaltol.

Baylor University
2
Synthesis, methods of using, and compositions of cycloalkylmethylamines

Reviva Pharmaceuticals
1
Discovery of a Highly Selective STK16 Kinase Inhibitor.

Chinese Academy of Sciences
1
Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders

Janssen Pharmaceutica
60
Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents

Bayer Intellectual Property
1
Inhibition of arginine aminopeptidase by bestatin and arphamenine analogues. Evidence for a new mode of binding to aminopeptidases.

University of Wisconsin
5
Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties.

University of Florida
3
Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.

Schering-Plough Research Institute
26
Design and Synthesis of Classical and Nonclassical 6-Arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as Antifolates.

Duquesne University
42
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.

AstraZeneca
9
Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.

National Taiwan University